

Fatty acid transport receptor soluble CD36 and dietary fatty acid pattern in type 2 diabetic patients: a comparative study

Merve Ekici¹, Ucler Kisa², Senay Arikian Durmaz³, Elif Ugur⁴ and Reyhan Nergiz-Unal^{4*}

¹Department of Nutrition and Dietetics, Faculty of Health Sciences, Kırıkkale University, 71100 Kırıkkale, Turkey

²Department of Medical Biochemistry, Faculty of Medical Sciences, Kırıkkale University, 71100 Kırıkkale, Turkey

³Department of Endocrinology, Faculty of Medical Sciences, Kırıkkale University, 71100 Kırıkkale, Turkey

⁴Department of Nutrition and Dietetics, Faculty of Health Sciences, Hacettepe University, 06100 Ankara, Turkey

(Submitted 9 June 2017 – Final revision received 12 September 2017 – Accepted 18 October 2017)

Abstract

Recently, it has been remarked that dietary fatty acids and fatty acid receptors might be involved in the aetiology of diabetes. Therefore, this study was conducted to determine the relationship between dietary fatty acid pattern, fatty food preferences and soluble CD36 (sCD36) and insulin resistance in type 2 diabetes mellitus (DM). The study was carried out with thirty-eight newly diagnosed type 2 DM patients and thirty-seven healthy volunteers, aged 30–65 years. In the study, socio-demographic characteristics, dietary fat type and fatty acid pattern of individuals were recorded. After anthropometric measurements were taken, blood CD36, glucose, TAG and insulin levels were analysed. The results showed that although the type of fatty acid intake did not differ between the groups ($P > 0.05$), the consumption of olive oil in the type 2 DM group was lower than the control group ($P < 0.05$). Mean blood glucose, insulin, insulin resistance, TAG and sCD36 levels were determined to be higher in the type 2 DM group ($P < 0.05$). However, there was no correlation between sCD36 levels and homeostatic model assessment of insulin resistance (HOMA-IR) value, blood insulin and TAG levels, waist circumference, dietary fatty acid pattern and food preferences in the type 2 DM group ($P > 0.05$). Crucially, elevated sCD36 levels increased the type 2 DM risk (OR 1.21, $P < 0.05$). In conclusion, sCD36 level may be a possible biomarker, independent from the dietary fatty acid pattern, for type 2 DM owing to its higher levels in these patients. Therefore, the new insights make CD36 attractive as a therapeutic target for diabetes.

Key words: Type 2 diabetes mellitus: CD36: Lipids

Diabetes mellitus (DM) is a metabolic disease that causes disorders of carbohydrate, fat and protein metabolism characterised by chronic hyperglycaemia⁽¹⁾. Globally, it was expected that DM cases will reach 438 million by 2030, in which type 2 DM was the most commonly diagnosed type^(1–3). Today, the most important approach used to prevent and reduce the occurrence of type 2 DM is dietary modifications in macronutrients as a primary and long-term strategy^(4,5).

Although the studies conducted in this regard are usually based on dietary carbohydrates, recent studies indicate that SFA and unsaturated fatty acids are also involved in the aetiology of diabetes owing to their function as signal molecules in various cellular processes including occurrence and progress of diabetes^(6,7). Although high levels of SFA in the membrane have adverse effects on insulin signalling, there are studies reporting that high levels of *n*-3 and *n*-6 fatty acids, among PUFA, might have a role in increasing insulin sensitivity^(8–10).

Although insulin signalling and insulin secretion have been generally investigated in studies related to type 2 DM, recent studies concluded that multifactorial causes, insulin, as well as

different peptides, may be involved in the aetiology of diabetes⁽¹¹⁾. The studies conducted on CD36 fatty acid transport (FAT) receptor have recently increased owing to its multi-functional properties. Soluble CD36 (sCD36) is an important multi-functional membrane receptor to participate fatty acid uptake and a recently detected in blood as a cell-free form and identified as a biomarker of the metabolic syndrome^(12–14). Thus, sCD36 might be associated with insulin resistance, obesity and low-grade inflammations. In some recent studies, it was also reported that CD36 has a wide range of expression and it may play a role in diabetes and selection of fatty foods, as well as the mentioned functions^(15–17).

Accordingly, human studies that examine the relationship between sCD36 level, dietary fatty acid pattern, and fatty food preferences in relation to insulin resistance in human nutrition are limited in the literature. Therefore, this study aimed to analyse the relationship between dietary fat and fatty acid pattern, fatty food preferences, insulin resistance and CD36 fatty acid receptor levels in newly diagnosed type 2 diabetic patients in comparison with healthy individuals.

Abbreviations: DM, diabetes mellitus; HOMA-IR, homeostatic model assessment of insulin resistance; sCD36, soluble CD36.

* **Corresponding author:** R. Nergiz-Unal, fax +90 312 3091310, email rnergiz@hacettepe.edu.tr; rnergizunal@gmail.com

Methods

The research was conducted on individuals between 30 and 65 years of age with newly diagnosed type 2 DM (n 38) who were admitted to the Endocrinology Outpatient Clinic of Kırıkkale University Faculty of Medicine, and healthy volunteers (n 37) who were selected in compliance with the BMI and age of patients, between October 2014 and June 2015. The sample size of this study was determined with power analysis at an 80% statistical power and 0.05% two-sided significance level. A total of 104 individuals were assessed for the research and the study was completed with seventy-five volunteers. To assess the potential influence of long-term blood glucose control impairment on sCD36 levels in newly diagnosed T2 DM patients, the study included those who had not started to receive any medication such as insulin and oral antidiabetic drugs. Individuals who did not meet the study criteria could not give a reliable diet trait or information, and those who wanted to quit were excluded from the study. Ethics committee approval suitable for the Declaration of Helsinki (Ethics Committee no. 12/03) was received from the Commission for Evaluation of Scientific Research at Kırıkkale University. Volunteers were interviewed face to face and a signed written consent form was obtained from each participant.

Anthropometric measurements

The body weight measurement was taken using an electronic scale sensitive to 0.1 kg (Tanita BC 420) and with appropriate garments while the participant was fasting⁽¹⁸⁾. Furthermore, body composition analysis was also determined by bioelectrical impedance analysis (Tanita BC 420)⁽¹⁹⁾. The height measurement was taken while standing without shoes and on a Frankfurt horizontal plane (eye triangle and top of tragus on the same line)⁽¹⁸⁾.

BMI (kg/m^2) was calculated from body weight (kg) and height (cm) measurements of the individuals. Individuals with a BMI between 18.5 and 24.9 kg/m^2 were classified as normal, those between 25.0 and 29.9 kg/m^2 were classified as pre-obese, those between 30.0 and 34.9 kg/m^2 were classified as first-degree obese, those between 35.0 and 39.9 kg/m^2 were classified as second-degree obese and those with a BMI of ≥ 40.0 kg/m^2 were classified as third-degree obese⁽¹⁸⁾.

Waist circumference was measured from the lowest circumference in the middle of the iliac prominence and the lowest rib of the individual by an inflexible measuring tape. Individuals were classified as risky (female: ≥ 80 cm; male: ≥ 94 cm) or at high risk (female: ≥ 88 cm; male: ≥ 102 cm) according to the waist circumference measurements⁽¹⁸⁾. Hip circumference was measured parallel to the ground from the highest point on the hip by an inflexible measuring tape. Waist:hip ratio was calculated by the waist circumference (cm)/hip circumference (cm) formula and their risk values were considered as ≥ 0.85 for women and ≥ 0.90 for men⁽¹⁸⁾.

Dietary intake and fat type consumption

In the study, individual daily food consumption was determined by the '24-h recall' method using a Food

Consumption Registration Form. Fatty acid type and fat intake amounts of the individuals were calculated using BeBIS 7.1 (Nutrition Information System) program. The type and frequency of fat or oil consumed and fatty food preferences by individuals on a daily diet was assessed by recording the FFQ⁽²⁰⁾.

Fasting blood glucose, soluble CD36, TAG, insulin and insulin resistance levels analysis

Fasting serum glucose and TAG concentrations were measured using a photometric assay method with an autoanalyser (Roche Diagnostics). Serum insulin levels were determined by electrochemiluminescence immunoassay with an autoanalyser (Roche Diagnostics). After drawing blood from each patient, the serum was isolated from the whole blood, snap-frozen and preserved at -80°C . sCD36 levels were measured using a commercially available ELISA kit (Glycoprotein IV (GP4); Human Elisa Kit Cloud-Clone Corp. Company; product no.: SEB530HU)⁽²¹⁾. Insulin resistance (homeostatic model assessment of insulin resistance; HOMA-IR) was calculated by the (fasting serum glucose (mg/dl) \times fasting insulin level ($\mu\text{U}/\text{ml}$))/405 formula⁽²²⁾.

Statistical data analysis

The distribution and skewness of the data were assessed by normality tests and the mean was expressed with means with their standard errors or standard deviations values. In comparison of the differences between the two independent groups, a non-parametric hypothesis test (Mann-Whitney U test) was used for numerical/quantitative data, whereas the Pearson's χ^2 test was used for qualitative data. Non-parametric Spearman's rank correlation analysis was performed to determine the relationship between numerical variables. Logistic regression analysis was performed for the risk assessment. Statistical significance was set at $P < 0.05$ and data analysis was performed with the Statistical Package for Social Sciences (SPSS version 23.0).

Results

General characteristics of participants

The study included thirty-eight (twenty-four females, fourteen males) newly diagnosed type 2 DM patients and thirty-seven healthy control (twenty-eight females, nine males) subjects. There was no statistically significant difference ($P > 0.05$) between the groups in terms of individual characteristics such as sex, marital status, educational status, regular physical activity and smoking status of individuals who were newly diagnosed with type 2 DM or healthy individuals (Table 1). The same demographic characteristics in both groups confirm that an appropriate control group was selected in order to make comparisons (Table 1). Although there was a significant difference in the mean age of the subjects between the groups, the facts that both groups were in the adult age range and sCD36 does not change with age indicate that the groups were chosen appropriately for the comparisons (Table 1).

Table 1. General characteristics of the participants in the study*
(Mean values and standard deviations; numbers and percentages; mean values with their standard errors)

Features	Type 2 DM						Control						P
	Female (n 24)		Male (n 14)		Total (n 38)		Female (n 28)		Male (n 9)		Total (n 37)		
	n	%	n	%	n	%	n	%	n	%	n	%	
Sex	24	63.2	14	36.8	38	100	28	75.7	9	24.3	37	100	0.35
Age (years)													0.00*
Mean		48.7		50.6		49.4		43.7		42.3		43.4	
SD		10.4		8.3		9.6		7.9		10.1		8.4	
Marital status													0.04
Married	17	70.8	13	92.9	30	78.9	25	89.3	7	77.8	32	86.5	
Single	1	4.2	0	0.0	1	2.6	2	7.1	2	22.2	4	10.8	
Divorced	6	25.0	1	7.1	7	18.4	1	3.6	0	0.0	1	2.7	
Education status													0.09
Not literate	3	12.5	0	0.0	3	7.9	0	0.0	0	0.0	0	0.0	
Primary school	14	58.3	4	28.6	18	47.4	13	46.4	0	0.0	13	35.1	
Middle school	6	25.0	1	7.1	7	18.4	4	14.3	0	0.0	4	10.8	
High school	0	0.0	5	35.7	5	13.2	6	21.4	3	33.3	9	24.3	
University	1	4.2	4	28.6	5	13.2	5	17.9	6	66.7	11	29.7	
Occupation													0.52
Housewife	22	91.7	0	0.0	22	57.9	23	82.1	0	0.0	23	62.2	
Self-employment	0	0.0	1	7.1	1	2.6	0	0.0	1	11.1	1	2.7	
Officer	1	4.2	6	42.9	7	18.4	4	14.3	5	55.6	9	24.3	
Other	1	4.2	7	49.9	8	21.0	1	3.6	3	33.3	4	10.8	
Presence of chronic diseases in the family													
Diabetes mellitus	16	66.7	8	57.1	24	63.2	16	57.1	3	33.3	19	51.4	0.20
Hypertension	17	70.8	6	42.9	23	60.5	10	35.7	3	33.3	13	35.1	0.02*
Other cardiovascular diseases	15	62.5	4	28.6	19	50.0	10	35.7	1	11.1	11	29.7	0.07
Smoking status	5	20.8	3	21.4	8	21.0	4	14.3	1	11.1	5	13.5	0.60
Regular physical activity	3	12.5	3	21.4	6	15.8	4	14.3	3	33.3	7	18.9	0.90
Type (walking)	3	12.5	3	21.4	6	15.8	4	14.3	3	33.3	7	18.9	0.72
Duration (min/d)													0.60
Mean		3.1		8.6		5.1		6.4		7.8		6.8	
SEM		8.5		18.8		13.3		19.5		2.3		17.9	

Dietary fatty acids and CD36 in diabetes

DM, diabetes mellitus.

* The χ^2 test was performed between the patient and the control groups for total participants.

Body composition and anthropometric measurements

The difference between the groups in terms of parameters of body composition such as total body fat (%), fat-free body mass (%), muscle mass (%), and body water (%) was not statistically significant ($P > 0.05$) when BMI classification was taken as a basis ($P > 0.05$) (data not shown).

The differences between the mean waist circumferences, measured for the determination of regional fatness in the body, of the control and type 2 DM patient groups were statistically significant ($P < 0.05$). Hip circumference measurements did not differ between the groups ($P > 0.05$), whereas the waist/hip ratio difference was statistically significant ($P < 0.05$). When the above-mentioned measurements are classified according to intersection points determined by the World Health Organisation, risky and high-risk waist circumference and high-risk waist:hip ratio were significantly more frequent in the diabetic group in comparison with the control group (Table 2).

Dietary fatty acids and dietary fatty acid pattern

Considering the dietary fat or oil type, it was determined that the most frequently consumed one in the patient and control groups was sunflower oil, followed by butter; the daily average consumption of sunflower oil and butter in the patient and control groups did not differ ($P > 0.05$). In contrast, the mean olive oil consumption was significantly higher in the control group than in the patient group ($P < 0.05$). In terms of the consumption of other dietary fat types including sunflower oil, maize oil, hazelnut oil, sesame oil, animal fat, butter, solid margarine and soft margarine, there was no significant difference between the groups ($P > 0.05$) (Table 3).

Furthermore, after taking daily food consumption records from individuals, the dietary fatty acid pattern was calculated from foods and drinks consumed by the participants. According to these data, the percentage of daily energy received from fat was higher in the control group ($P < 0.05$). However, there was no significant difference between the groups for fatty acid type, cholesterol, *n-3* and *n-6* PUFA ($P > 0.05$). The ratio of *n-6:n-3* PUFA was approximately 15:1 in both groups (Table 4).

Serum soluble CD36, glucose, insulin, TAG levels and insulin resistance

Fasting blood glucose levels of the individuals who participated in the study were 9.2 (SEM 0.67) mmol/l in the patient group and 5.2 (SEM 0.05) mmol/l in the control group ($P < 0.05$) (data not shown). sCD36 levels in the blood were analysed as 17.7 (SEM 1.0) ng/ml in the patient group and 12.5 (SEM 0.7) ng/ml in the control group ($P < 0.05$). Mean blood insulin levels and HOMA-IR values were 16.5 (SEM 1.4) μ U/ml and 6.2 (SEM 0.5), respectively, in the patient group, and 11.4 (SEM 0.8) μ U/ml and 2.3 (SEM 0.1), respectively, in the control group ($P < 0.05$). When the data were assessed based on sexes, this significance was only parallel to HOMA-IR and sCD36 levels. Blood TAG levels of individuals were 2.13 (SEM 0.19) mmol/l in the diabetic group and 1.51 (SEM 0.19) mmol/l in the control group ($P < 0.05$) (Table 5).

Table 2. Anthropometric measurements of the participants† (Numbers and percentages)

Measurements	Type 2 DM						Control						P		
	Female		Male		Total		Female		Male		Total				
	n	%	n	%	n	%	n	%	n	%	n	%			
BMI groups (kg/m ²)															
18.50–24.99	0.0	0.0	1.0	7.1	1.0	2.6	6.0	21.4	2.0	22.2	8.0	21.6	0.05		
25.00–29.99	3.0	37.5	4.0	28.6	7.0	18.4	6.0	21.4	4.0	44.4	10.0	27.0			
30.00–34.99	9.0	12.5	8.0	57.1	17.0	44.7	7.0	25.0	3.0	33.3	10.0	27.0			
35.00–39.99	6.0	25.0	1.0	7.1	7.0	18.4	3.0	10.7	0.0	0.0	3.0	8.1			
> 40	6.0	25.0	0.0	0.0	6	15.8	6.0	21.4	0.0	0.0	6.0	16.2			
Waist circumference (risk)‡	24	100	13	92.9	37	97.4	23	82.1	7	77.8	30	81.1	0.03*		
Waist circumference (high risk)‡	24	100	12	85.7	36	94.7	20	71.4	6	66.7	26	70.3	0.02*		
Waist:hip ratio (high risk)‡	21	87.5	13	92.9	34	89.5	17	60.7	8	88.9	25	67.6	0.04*		

DM, diabetes mellitus.

* $P < 0.05$ is significant.

† The χ^2 test was performed between the patients and the control groups for total participants.

‡ WHO cut-off points and risk of metabolic complications (WHO Expert Consultation).⁽¹⁸⁾

Table 3. Dietary oil or fat types and daily consumption amounts of the participants† (Mean values with their standard errors)

Oil/fat (g/d)	Type 2 DM						Control						P
	Female		Male		Total		Female		Male		Total		
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
Olive oil	3.1	1.7	10.1	3.3	5.7	1.7	10.2	1.8	16.8	5.2	11.8	1.9	0.01*
Sunflower oil	36.8	4.2	36.8	6.5	36.8	3.5	31.7	3.1	36.0	6.9	32.7	2.9	0.42
Maize oil	0.9	0.9	5.9	4.3	2.7	1.7	1.1	0.8	0.1	0.0	0.8	0.6	0.62
Hazelnut oil	1.2	1.2	0.0	0.0	0.7	0.7	0.4	0.4	0.1	0.0	0.3	0.3	1.00
Sesame oil	0.1	0.0	0.3	0.3	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.32
Animal fat	0.1	0.0	0.9	0.9	0.3	0.3	0.1	0.0	0.9	0.9	0.2	0.2	0.45
Butter	5.1	1.7	6.1	2.6	5.5	1.4	6.2	1.5	11.3	2.9	7.5	1.4	0.12
Margarine (solid)	3.0	0.9	2.3	1.4	2.7	0.8	2.1	0.8	0.5	0.5	1.7	0.6	0.13
Margarine (soft)	0.4	0.4	0.1	0.0	0.3	0.3	0.1	0.0	0.0	0.0	0.1	0.0	1.00

DM, diabetes mellitus.

* $P < 0.05$ is significant.

† The Mann–Whitney U test was performed between the patients and the control groups for total participants.

Table 4. Dietary fat and fatty acids pattern of the participants (Mean values with their standard errors)

	Type 2 DM						Control						P
	Female		Male		Total		Female		Male		Total		
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
Fat (%)†	35.0	2.1	31.7	1.9	33.8	1.5	41.1	1.8	35.0	1.8	39.6	1.4	0.01*
Fat (g)†	67.2	5.6	79.0	5.0	71.6	4.1	67.8	4.6	87.8	5.8	72.6	4.0	0.85
PUFA (%)†	9.9	0.9	8.9	0.7	9.5	0.6	11.2	0.9	8.0	1.5	10.4	5.0	0.67
PUFA (g)†	19.0	2.2	22.3	2.3	20.2	1.6	18.9	1.9	20.1	4.1	19.2	1.7	0.67
MUFA (%)†	10.8	0.7	10.4	0.8	10.6	0.5	13.4	0.7	12.9	0.7	13.3	0.6	0.50
MUFA (g)†	21.1	2.3	25.5	2.0	22.7	1.7	21.7	1.6	32.1	2.6	24.3	1.5	0.50
SFA (%)†	11.4	1.1	10.3	0.9	11.0	0.8	13.7	1.0	11.8	1.0	13.2	0.8	0.69
SFA (g)†	21.6	2.1	24.9	2.2	22.8	1.6	22.0	1.7	29.0	2.3	23.7	1.5	0.69
<i>n</i> -3 PUFA (g)	2.3	0.6	1.6	0.3	2.0	0.4	1.3	0.1	1.6	0.3	1.3	0.1	0.64
<i>n</i> -6 PUFA (g)	16.6	2.0	20.6	2.2	18.1	1.5	17.6	1.9	18.4	3.9	17.8	1.7	0.68
<i>n</i> -6: <i>n</i> -3 ratio	13.2	1.9	15.6	2.0	14.1	1.4	15.5	1.9	11.9	2.1	14.6	1.5	0.33
Cholesterol (mg)†	221	25.9	247.1	38.8	230.7	21.5	226.0	21.5	363.4	59.4	259.4	23.4	0.37
SCFA (g)†	1.1	0.1	1.3	0.2	1.2	0.1	1.1	0.1	1.4	0.2	1.1	0.1	0.93
MCFA (g)†	0.8	0.1	0.9	0.1	0.9	0.0	0.8	0.0	1.0	0.1	0.8	0.0	0.73
LCFA (g)†	59.6	5.3	70.2	4.6	63.5	3.8	58.9	4.1	71.8	5.7	62.1	0.78	0.78

DM, diabetes mellitus; MCFA, medium-chain fatty acids; LCFA, long-chain fatty acids.

* $P < 0.05$ is significant.

† The data were evaluated with the t test, and the rest of the data were assessed using the Mann–Whitney U test for total participants within the groups.

Table 5. Fasting serum levels of soluble CD36 (sCD36), insulin, TAG and estimation of insulin resistance (homeostatic model assessment of insulin resistance; HOMA-IR)† (Mean values with their standard errors)

Parameters	Type 2 DM				Control				P				
	Female		Male		Female		Male			Total			
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM		Mean	SEM		
sCD36 (ng/ml)	18.3	1.5	16.7	1.3	17.7	1.0	12.1	0.9	14.2	1.1	12.5	0.7	0.00*
Insulin (µU/ml)	18.1	1.9	13.9	2.0	16.5	1.4	10.6	0.8	14.0	2.2	11.4	0.8	0.00*
HOMA-IR	6.5	0.7	5.7	0.7	6.2	0.5	2.2	0.1	2.8	0.4	2.3	0.1	0.00*
TAG (mmol/l)	2.25	0.25	1.92	0.28	2.13	0.19	1.18	0.10	1.97	0.64	1.51	0.19	0.00*

DM, diabetes mellitus.

* $P < 0.05$ is significant.

† The Mann-Whitney U test was performed between the patient and the control groups for total participants.

The logistic regression analysis results showed that elevated sCD36 levels were associated with higher type 2 DM risk (OR 1.21; 95% CI 1.03, 1.44; $P=0.02$), whereas increased consumption of olive oil was associated with lower type 2 DM risk (OR 0.92; 95% CI 0.86, 0.99; $P=0.03$).

Correlation analysis was performed between sCD36 levels and insulin and TAG levels in the serum, HOMA-IR, anthropometric measurements (BMI, waist circumference and waist:hip ratio) and dietary fatty acids in the individuals newly diagnosed with type 2 DM. However, there was no significant relationship between sCD36 levels in the serum and these parameters ($P > 0.05$) (data not shown). Correlation graphic in Fig. 1 shows that there was no relationship between sCD36, which had a difference of means in the patient and the control groups, blood insulin level ($r 0.02$, $P=0.88$), HOMA-IR value ($r 0.13$, $P=0.63$), blood TAG level ($r 0.20$, $P=0.24$) and the waist circumference ($r -0.02$, $P=0.91$) (Fig. 1(a) and (d)).

Serum soluble CD36 level, dietary fatty acid pattern and food preferences

Correlation analysis (Spearman's rank correlation coefficient test) was performed for the relationship between total fat (g), PUFA (g), MUFA (g), SFA (g), $n-3$ PUFA (g), $n-6$ PUFA (g), cholesterol (mg) intake and $n-6:n-3$ ratio and sCD36 level. Hence, there was no significant difference ($P > 0.05$) between the sCD36 levels and dietary fatty acid pattern of the newly diagnosed type 2 DM patient group and the control group (Table 6).

Fat, carbohydrate or protein food preferences were also recorded based on individual declaration, and these results are shown in Table 7. However, significant difference between food preferences in patient and control groups was determined only in carbohydrate-containing food preference, not in fatty food preference. A percentage of 21.6% in the control group and 47.4% in the diabetic patient group stated that they had a desire to eat carbohydrate foods ($P < 0.05$) (Table 7). Moreover, the relationships of serum sCD36 values for individuals diagnosed with type 2 DM and in the control group were also assessed based on their food preferences. On the other hand, serum sCD36 values in both the diabetic patient group and control group were not affected by fat, carbohydrate and protein food preferences ($\chi^2 (2)=0.82$, $\chi^2 (2)=4.94$ $P > 0.05$).

Discussion

According to our principal findings, serum sCD36 levels in type 2 DM patients elevated even if DM was newly diagnosed. Fatty acid pattern, abdominal adiposity, visceral fat and fatty acids transporters such as CD36 may be correlated with development of type 2 DM. According to recent studies, sCD36 levels are higher in type 2 DM patients, and this condition is considered to be closely correlated with insulin resistance^(23–26). In this study conducted in parallel to this, the sCD36 level was significantly higher in type 2 DM patients (17.7 (SEM 1.0) ng/ml) than in the control group (12.5 (SEM 0.7) ng/ml). Similarly, in




Fig. 1. Relationship between CD36 and insulin, insulin resistance, TAG and waist circumference levels of patients with type 2 diabetes mellitus. Fasting serum insulin (a), insulin resistance (homeostatic model assessment of insulin resistance; HOMA-IR) (b), TAG levels (c) and waist circumference measurement (d) correlation graphs of patients with type 2 diabetes mellitus are presented. sCD36, soluble CD36.

the studies by Alkhatatbeh *et al.*⁽²⁵⁾ and Liani *et al.*⁽²⁶⁾, sCD36 levels were significantly higher in diabetic individuals than in their control groups. High sCD36 levels may be considered to be involved in the pathogenesis of metabolic processes taking place commonly in DM and obesity, such as the use of muscle lipids, accumulation of TAG in the adipose tissue, fat absorption in the intestines and use of the substrate in the heart, as CD36 can bind to fatty acids and facilitate their transport into the cell^(15,27–30). Therefore, abdominal adiposity, inflammation and lipid profile indicators should be assessed together in diabetic individuals. In addition, in the literature, the role of CD36 as an oxidant LDL receptor in macrophages is correlated with vascular damage associated with diabetes^(1,26,28,30,31).

In type 2 DM patients, insulin resistance may be affected by sCD36 levels. Interestingly, we found a positive correlation between HOMA-IR and sCD36 levels in our study. Similar to this, Handberg *et al.*⁽²³⁾ previously proposed the relationship between insulin resistance and blood sCD36 levels and higher level of sCD36 in type 2 DM patients to reveal a role of sCD36 in the homeostasis of glucose. Studies conducted on cardiomyocytes indicated that CD36 may be involved in GLUT4-mediated glucose transport, and cells may be involved in energy substrate intake⁽³²⁾. Moreover, in this study, blood TAG and CD36 levels, which are related to visceral fat in organs such as heart and liver, were found to be correlated. In some studies, the relationship between CD36 and TAG levels was examined owing to its involvement in lipid metabolism, FAT and proposed some haploid gene variants^(32,33). However, controlled human studies are limited to assess the relationship between CD36 and diabetes.

On the other hand, studies showed that CD36 receptor played a role as a chemo-sensory factor in different flavours and smells in selection of fatty foods^(34,35). Rodent studies found that CD36 takes place particularly in the lingual epithelium where taste buds are present, and it has high affinity with long-chain fatty acids^(27,34,35). However, in this study, it was determined that sCD36 levels and dietary preferences in type 2 DM patients were not associated. The reason for this may be owing to the small size of the sample, similarity of body composition and the fact that these data were recorded based on the participants' own declarations.

In addition to genetic predisposition, obesity and food habits are among the risk factors in development of DM^(1,5,36–38). Fat distribution in the body and the degree of obesity are also important compounding factors in insulin sensitivity⁽³⁸⁾. In this study, the waist circumference (cm) and waist/hip ratio, among the risk factors and determining factors for the prognosis and metabolic effects of type 2 DM^(39–41), differed between the groups; however, the values in the obtained data were significantly higher in the patient group. Shah *et al.* found that waist circumference and waist/hip ratios were significantly higher in the diabetic group than in the control group⁽⁴¹⁾. Thus, abdominal or visceral adiposity could cause lipogenesis and inflammation-mediated dysfunction of insulin signalling pathways. Nevertheless, abdominal fat and CD36 were not correlated in this study.

The energy density of the diet supports the hypothesis that fatty acid pattern, abdominal adiposity and visceral fat and fatty acids transporters such as CD36 and insulin signalling may be correlated with type 2 DM development. Although dietary energy density and carbohydrates are being investigated in

Table 6. Relationship between soluble CD36 (sCD36) level and dietary fatty acid pattern†

	Type 2 DM						Control					
	Female		Male		Total		Female		Male		Total	
	r	P	r	P	r	P	r	P	r	P	r	P
Total fat (g)	-0.07	0.73	0.49	0.06	0.10	0.53	-0.14	0.46	-0.08	0.83	0.04	0.81
PUFA (g)	-0.08	0.68	0.28	0.31	0.06	0.72	-0.00	0.98	0.21	0.57	0.04	0.80
MUFA (g)	-0.08	0.70	0.59	0.02	0.11	0.49	-0.15	0.42	-0.21	0.57	0.07	0.66
SFA (g)	0.03	0.86	0.23	0.41	0.10	0.53	-0.27	0.16	0.21	0.57	-0.03	0.84
n-3 PUFA (g)	0.004	0.99	0.35	0.21	0.10	0.53	0.08	0.65	0.23	0.54	0.20	0.22
n-6 PUFA (g)	-0.19	0.35	0.20	0.47	-0.06	0.69	0.00	0.99	0.16	0.66	0.03	0.84
n-6:n-3 ratio	-0.09	0.67	-0.10	0.72	-0.02	0.90	0.02	0.89	0.06	0.86	-0.05	0.74
Cholesterol (mg)	-0.28	0.18	0.22	0.44	-0.07	0.64	-0.24	0.21	0.10	0.79	-0.02	0.86

DM, diabetes mellitus.

* $P < 0.05$ is significant.

† The Spearman's rank correlation coefficient test was performed between the patient and the control groups for total participants.

Table 7. Fat, carbohydrate or protein consisting food preferences of the participants† (Numbers and percentages)

Preferences	Type 2 DM		Control		χ^2	P
	n	%	n	%		
Fat	9	23.7	13	35.1	0.72	0.39
Carbohydrate	18	47.4	8	21.6	3.84	0.04*
Protein	11	28.9	16	43.2	0.92	0.33

* $P < 0.05$ is significant.

† The χ^2 test was performed between the patient and the control groups for total participants.

studies on obesity and diabetes, fat and fatty acids were not largely investigated. However, it was reported in recent limited studies that dietary fatty acids might play an important role in postprandial glycaemic control and development of diabetes^(6,7,42,43). Conversely, the relationships between sCD36 levels and the amount of daily dietary fat intake, fat type, fatty acids pattern and TAG levels were not significant in this study. Similarly, in the cross-sectional study conducted by Breen *et al.*⁽⁴⁴⁾, it was reported that the contribution percentages of total fat, PUFA, MUFA and SFA for the daily energy intake were not different in diabetic patients in comparison with the control group. In a study conducted by Mumu *et al.*⁽⁴⁵⁾ on DM patients, the contribution percentages of total fat, PUFA and MUFA for the daily energy intake in patients were higher than their control group. Similarly, the fact that the ratio of n-6/n-3 fatty acids is about 15 in studies mentioned above is a consequence that is required to be assessed in degenerative diseases such as diabetes. The main reason for the differences in the results here may be that the daily food consumption records are taken for 1 d, and other dietary devastating factors such as socioeconomic level and geographical conditions are not included.

Furthermore, the amount of daily fat intake is as important as the composition of fatty acids⁽⁴⁶⁾. Current studies suggest that olive oil has positive effects especially on endothelial function, inflammation and oxidative stress owing to the MUFA and phytochemical contents of olive oil⁽⁴⁷⁾. In this study, it was determined that the consumption of olive oil was significantly lower in the group of type 2 DM patients than in the control group. Similarly, other studies emphasised the beneficial effects of MUFA and olive oil consumption in diabetes^(43,46,47). In another study, it was found that consumption of olive oil in diabetic patients was correlated with a decrease in fasting blood glucose, TAG, total cholesterol and LDL-cholesterol⁽⁴⁷⁾. Thus, consumption of olive oil may have positive effects on blood glucose and lipid profile in patients with type 2 DM.

In summary, this study is one of the rare nutrition studies that examines the relationship between sCD36 fatty acid receptor and insulin resistance in individuals with type 2 DM. In conclusion, sCD36 levels may be an important parameter for patients with type 2 DM owing to its higher concentration in diabetic patients in comparison with the control group. More extensive clinical nutrition studies that examine the relationships among CD36 fatty acid receptor, insulin resistance and dietary fatty acid pattern might be considered for further evidence.

Acknowledgements

The authors thank the volunteers for their participation in the study.

This study was partly supported by Hacettepe University Scientific Research Projects Coordination Unit (Ankara, Turkey) for RNU.

M. E. carried out the data collection, analysis and helped to draft the manuscript. U. K. carried out the blood analysis. S. A. D. facilitated the data collection from the participants and finalised the manuscript. E. U. helped to finalise and submit the manuscript. R. N.-U. designed the study, conducted the data collection and analysis and finalised the manuscript. All authors read and approved the final manuscript.

The authors declare that there are no conflicts of interest.

Preliminary data of the study were presented as a poster in the 41st FEBS Congress, and the abstract was published in the *FEBS Journal*, Volume 283, Supplement, 1 September 2016.

References

- Gautam S & Banerjee M (2011) The macrophage Ox-LDL receptor, CD36 and its association with type II diabetes mellitus. *Mol Genet Metab* **102**, 389–398.
- American Diabetes Association (2015) Standards of medical care in diabetes. *Diabetes Care* **38**, Suppl., S1–S2.
- International Diabetes Federation (2009) *International Diabetes Federation Diabetes Atlas*. Brussels: International Diabetes Federation.
- Canadian Diabetes Association (1999) Guidelines for the nutritional management of diabetes mellitus in the new millennium. *Can J Diabetes* **23**, 56–69.
- Redmon B, Caccamo D, Flavin P, *et al.* (2014) Diagnosis and management of type 2 diabetes mellitus in adults. <https://guideline.gov> (accessed June 2017).
- Liu L, Li Y, Guan C, *et al.* (2010) Free fatty acid metabolic profile and biomarkers of isolated post-challenge diabetes and type 2 diabetes mellitus based on GC-MS and multivariate statistical analysis. *J Chromatogr B Analyt Technol Biomed Life Sci* **878**, 2817–2825.
- Xu W, Zhang L, Huang Y, *et al.* (2012) Fatty acid metabolic profiles and biomarker discovery for type 2 diabetes mellitus using graphical index of separation combined with principal component analysis and partial least squares-discriminant analysis. *Chemometr Intell Lab Syst* **118**, 173–179.
- Siri-Tarino PW, Sun Q, Hu FB, *et al.* (2010) Saturated fat, carbohydrate, and cardiovascular disease. *Am J Clin Nutr* **91**, 502–509.
- Flachs P, Rossmesl M & Kopecky J (2014) The effect of *n*-3 fatty acids on glucose homeostasis and insulin sensitivity. *Physiological Research* **63**, Suppl., S98–S118.
- Lalia AZ & Lanza IR (2016) Insulin-sensitizing effects of omega-3 fatty acids: lost in translation? *Nutrients* **8**, 329.
- Bergman R & Ader M (2000) Free fatty acids and pathogenesis of type 2 diabetes mellitus. *Trends Endocrinol Met* **11**, 351–356.
- Kuijpers MJ, De Witt S, Nergiz-Unal R, *et al.* (2014) Supporting roles of platelet thrombospondin-1 and CD36 in thrombus formation on collagen. *Arterioscler Thromb Vasc Biol* **34**, 1187–1192.
- Nergiz-Unal R, Lamers MM, van Kruchten R, *et al.* (2011) Signaling role of CD36 in platelet activation and thrombus formation on immobilized thrombospondin or oxidized low-density lipoprotein. *J Thromb Haemost* **9**, 1835–1846.
- Febbraio M & Silverstein RL (2007) CD36: implications in cardiovascular disease. *Int J Biochem Cell Biol* **39**, 2012–2030.
- Nergiz-Unal R, Rademakers T, MEM Cosemans J, *et al.* (2011) CD36 as a multiple-ligand signaling receptor in atherothrombosis. *Cardiovasc Hematol Agents Med Chem* **9**, 42–55.
- Thorne RF, Mhaidat NM, Ralston KJ, *et al.* (2007) CD36 is a receptor for oxidized high density lipoprotein: implications for the development of atherosclerosis. *FEBS Lett* **581**, 1227–1232.
- Lynes MD & Widmaier EP (2011) Involvement of CD36 and intestinal alkaline phosphatases in fatty acid transport in enterocytes, and the response to a high-fat diet. *Life Sci* **88**, 384–391.
- World Health Organization (2011) *Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation*. Geneva: WHO.
- Bohm A & Heitmann BL (2013) The use of bioelectrical impedance analysis for body composition in epidemiological studies. *Eur J Clin Nutr* **67**, Suppl. 1, S79–S85.
- Rakıcıoğlu N & Akal Yıldız E (2011) Energy and nutrient intake and food patterns among Turkish university students. *Nutr Res Pract* **5**, 117–123.
- Nergiz-Unal R, Kuijpers MJ, de Witt SM, *et al.* (2013) Atheroprotective effect of dietary walnut intake in ApoE-deficient mice: involvement of lipids and coagulation factors. *Thromb Res* **131**, 411–417.
- Rössner SM, Neovius M, Mattsson A, *et al.* (2010) HOMA-IR and QUICKI: decide on a general standard instead of making further comparisons. *Acta Paediatr* **99**, 1735–1740.
- Handberg A, Levin K, Hojlund K, *et al.* (2006) Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. *Circulation* **114**, 1169–1176.
- Febbraio M, Hajjar DP & Silverstein RL (2001) CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. *J Clin Invest* **108**, 785–791.
- Alkhatatbeh M, Enjeti A, Acharya S, *et al.* (2013) The origin of circulating CD36 in type 2 diabetes. *Nutr Diabetes* **3**, e59.
- Liani R, Halvorsen B, Sestili S, *et al.* (2012) Plasma levels of soluble CD36, platelet activation, inflammation, and oxidative stress are increased in type 2 diabetic patients. *Free Radic Biol Med* **52**, 1318–1324.
- Christiaens V, Van Hul M, Lijnen HR, *et al.* (2012) CD36 promotes adipocyte differentiation and adipogenesis. *Biochim Biophys Acta* **1820**, 949–956.
- Park YM (2014) CD36, a scavenger receptor implicated in atherosclerosis. *Exp Mol Med* **46**, e99.
- Handberg A, Lopez-Bermejo A, Bassols J, *et al.* (2009) Circulating soluble CD36 is associated with glucose metabolism and interleukin-6 in glucose-intolerant men. *Diab Vasc Dis Res* **6**, 15–20.
- Martin C, Chevrot M, Poirier H, *et al.* (2011) CD36 as a lipid sensor. *Physiol Behav* **105**, 36–42.
- Atamer A, Ovunc AO, Yesil A, *et al.* (2013) Evaluation of leptin and insulin resistance in patients with cholelithiasis. *Indian J Biochem Biophys* **50**, 266–272.
- Angin Y, Schwenk RW, Nergiz-Unal R, *et al.* (2014) Calcium signaling recruits substrate transporters GLUT4 and CD36 to the sarcolemma without increasing cardiac substrate uptake. *Am J Physiol Endocrinol Met* **307**, E225–E236.
- Ramos-Arellano LE, Salgado-Bernabé AB, Guzmán-Guzmán IP, *et al.* (2013) CD36 haplotypes are associated with lipid profile in normal-weight subjects. *Lipids Health Dis* **12**, 167.
- Abumrad NA (2005) CD36 may determine our desire for dietary fats. *J Clin Invest* **115**, 2965.

35. Laugerette F, Passilly-Degrace P, Patris B, *et al.* (2005) CD36 involvement in orosensory detection of dietary lipids, spontaneous fat preference, and digestive secretions. *J Clin Invest* **115**, 3177.
36. Ekoe JM, Punthakee Z, Ransom T, *et al.* (2013) Screening for type 1 and type 2 diabetes. *Can J Diabetes* **37**, Suppl. 1, S12–S15.
37. Ozougwu O (2013) The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. *J Physiol Pathophysiol* **4**, 46–57.
38. Boffetta P, McLerran D, Chen Y, *et al.* (2011) Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. *PLoS ONE* **6**, e19930.
39. Saikumar P, Sudha D & Chandraselvi E (2014) Body mass index changes in patients with type 2 diabetes mellitus. *World Appl Sci J* **30**, 1238–1242.
40. Vazquez G, Duval S, Jacobs DR, *et al.* (2007) Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. *Epidemiol Rev* **29**, 115–128.
41. Shah A, Bhandary S, Malik S, *et al.* (2009) Waist circumference and waist-hip ratio as predictors of type 2 diabetes mellitus in the Nepalese population of Kavre District. *Nepal Med Coll J* **11**, 261–267.
42. Rivellese AA & Lilli S (2003) Quality of dietary fatty acids, insulin sensitivity and type 2 diabetes. *Biomed Pharmacother* **57**, 84–87.
43. Salas-Salvado J, Martinez-Gonzalez MA, Bullo M, *et al.* (2011) The role of diet in the prevention of type 2 diabetes. *Nutr Metab Cardiovasc Dis* **21**, Suppl. 2, B32–B48.
44. Breen C, Ryan M, McNulty B, *et al.* (2014) High saturated-fat and low-fibre intake: a comparative analysis of nutrient intake in individuals with and without type 2 diabetes. *Nutr Diabetes* **4**, e104.
45. Mumu SJ, Saleh F, Afnan F, *et al.* (2009) Pattern of dietary intake among newly diagnosed type 2 diabetic subjects with hypercholesterolemia. *Pak J Nutr* **8**, 721–724.
46. Evert AB, Boucher JL, Cypress M, *et al.* (2013) Nutrition therapy recommendations for the management of adults with diabetes. *Diabetes Care* **36**, 3821–3842.
47. Al Jamal AR & Ibrahim A (2011) Effects of olive oil on lipid profiles and blood glucose in type 2 diabetic patients. *Int J Diabetes Metab* **19**, 19–22.